Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Management
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • Scientific Advisory Committee
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
      • Sponsor/ Advisor
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Tag: Financials & Corporate

Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux

07/03/202007/09/2020

July 3, 2020 – 6:00 pm CEST   Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]

Onxeo: report on the Extraordinary General Meeting of June 19, 2020

06/19/202006/19/2020

Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo offre 10,7% de son capital à Invus – Biotech Finances

06/15/202006/15/2020

(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]

BFM Business Intégrale Bourse : Onxeo, Company of the Day

06/10/202006/11/2020

  Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]

Onxeo announces a capital increase of €7.3 million by private placement to Invus and Financière de la Montagne, the Company’s historical shareholder

06/09/202006/08/2020

The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022                 Paris […]

Onxeo announces that the Shareholders’ Meeting of May 29, 2020 has approved all ordinary resolutions

05/29/202005/29/2020

The Extraordinary General Meeting will be held on June 19, 2020 on the second call   Paris (France), May 29, […]

Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation

05/27/202005/29/2020

Paris (France), May 27, 2020 – 8.45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Publication of the 2019 Universal Registration Document

04/27/202005/07/2020

Paris (France), April 27, 2020 – 7.00 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

Onxeo’s Joint General Meeting in camera on May 29, 2020: availability of preparatory documents and live webcast login information

05/07/202005/07/2020

Paris (France), May 7, 2020 – 7:30 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

Onxeo Will Publish Its Annual Results on April 17, 2020

03/27/202004/01/2020

The Annual General Meeting will be held on May 29, 2020 Paris (France), March 27, 2020 – 8:30 pm CET […]

Onxeo Publishes Shareholder Newsletter

01/20/202003/13/2020

Paris (France), January 20, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

2019 Full year report on the liquidity contract

01/06/202003/13/2020

  Dowload the press release

Onxeo Announces its Financial Agenda for 2020

12/09/201903/13/2020

  Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]

“La France bouge” – Europe 1 : Interview of Judith Greciet

02/04/202003/13/2020

(in French only)   Watch the interview  

Onxeo Enters into Settlement Agreement with SpePharm and SpeBio

02/11/202003/13/2020

Settlement agreement fully resolves long-lasting litigation between the parties and all related proceedings Settlement terms have no impact on Onxeo’s […]

LesEchos/Investir–Presentation of Judith Greciet at Direct Dirigeants event

11/06/201903/13/2020

(in French only)

Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.

11/05/201911/05/2019

Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000

10/17/201911/05/2019

The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]

Publication of 2017 Registration Document

04/25/201810/08/2019

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]

Onxeo to Present Corporate Overview at the H.C. Wainwright Annual Global Life Sciences Conference

04/09/201810/04/2019

Advancing innovation towards breakthrough cancer therapies Paris, April 9, 2018 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ […]

Combined General Meeting on May 16, 2018

04/25/201810/04/2019

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]

Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update

03/29/201810/04/2019

Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON™, […]

Meet the Onxeo Team during the 2017 J.P. Morgan Healthcare Conference

12/22/201610/03/2019

January 9-12, 2017 in San Francisco, CA  In 2016, Onxeo has achieved a number of significant milestones, positioning the Company […]

Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC

04/04/201610/03/2019

Paris (France), Copenhagen (Denmark),  – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of […]

Passing on Onxeo’s Extraordinary and Ordinary General Meeting

04/06/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Onxeo First Quarter 2016 Financial Information and Business Update

04/28/201610/03/2019

Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext […]

Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco

10/10/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]

Publication of Shareholder Letter

10/12/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan […]

Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update

10/25/201610/03/2019

Clinical development plan in line with objectives Livatag® on track to deliver its next important milestone with 90% of patients […]

Onxeo to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference

11/28/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]

Consolidated turnover for 2010

02/10/201110/03/2019

Exceptional performance linked to international licensing agreements BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and […]

The structure of BioAlliance Pharma’s turnover for Q3 2010 reflects the dynamism of the company’s American and European collaborations

10/21/201010/03/2019

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today […]

Onxeo launches a capital increase by means of an accelerated book-build offering

06/19/201710/03/2019

Paris (France), June 19, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the […]

Onxeo successfully raises €15 Million with US and European investors

06/20/201710/03/2019

Offering upsized in response to investor demand   Paris (France), June 20, 2017 – 08:00 am CEST – Onxeo S.A. […]

Onxeo Reports First-Half 2017 Results and Business Update

07/28/201710/03/2019

Sound cash position of €27.7m as at June 30, 2017 and cash runway till Q1 2019 Development of the core […]

Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma

07/31/201710/03/2019

Transaction confirms Onxeo’s strategic focus on innovative orphan oncology drugs Paris (France), July 31, 2017 – 05:45 pm CEST – […]

Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm

10/17/201710/03/2019

Paris (France), October 17, 2017 – 10 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

Financial Agenda 2018

01/23/201810/03/2019

  Onxeo Announces its Financial Agenda for 2018 Paris (France), January 23, 2018 – 5:45 pm CET – Onxeo S.A. […]

Onxeo to attend Key Investor and Partnering Conferences in H1 2018

01/03/201809/24/2019

Paris (France), January 3, 2018 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

Full-year financial results for 2010

03/03/201109/17/2019

 The company posts a profit as a result of an exceptional revenue High potential for further growth Paris, March 3, […]

Onxeo to Attend Key Investor and Scientific Conferences

09/11/201909/12/2019

Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), […]

Onxeo announces the great success of its share capital increase with shareholders’ preferential subscription rights

12/12/201409/11/2019

Total demand of Approximately 76.4 million euros, i.e. an oversubscription rate of 216% of the offer Full exercise of the […]

Onxeo announces closing of DNA Therapeutics acquisition

03/25/201609/11/2019

Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq […]

Onxeo Reports 2015 Full-Year Results and Provides Business Update

02/26/201609/11/2019

2015: Successful year of consolidation and major achievements in all lead programs Progression of Phase III trial of Livatag® in […]

Publication of 2015 Reference Document

05/02/201609/11/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Onxeo Secures $7.5 Million of Non-dilutive Capital from SWK Holdings Corporation Through Sale of Rights related to Future Beleodaq® Royalties

06/07/201809/11/2019

  Transaction reinforces Company’s cash position and proceeds will be fully allocated to the advancement of Onxeo’s pipeline, including its […]

BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions

04/08/201409/11/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma Publishes its first Shareholder Newsletter

04/29/201409/11/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Announces The Evolution And Reinforcement Of Its Board Of Directors

01/25/201609/10/2019

Drs. Jean-Pierre Kinet of Harvard Medical School, and Jean-Pierre Bizzari, international expert in Oncology, join the Onxeo Board of Directors […]

Meetings with the financial community during the 2nd semester of 2015

07/08/201509/06/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces its […]

Posts navigation

Older posts

NEWS & EVENTS

  • Press Releases
  • Events & Presentations
  • Shareholder Letters
  • Media
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

185 Alewife Brook Parkway
Suite 210, Cambridge, MA 02138
(617) 648-8674

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2023 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress